Potentiation of the antimycobacterial activity of bedaquiline, clofazimine, and doxycycline against Mycobacterium smegmatis by several natural product-based compounds is putatively via efflux inhibition

<ns3:p> Background <ns3:italic>Mycobacterium tuberculosis</ns3:italic> ( <ns3:italic>Mtb</ns3:italic> ), the causative agent of tuberculosis (TB), is the leading cause of death due to a single infectious pathogen globally. The increasing prevalence of drug-resistant <ns3:italic>Mtb</ns3:italic> strains underscores the pressing need for the development of new antimycobacterial drugs with novel mechanisms of action. Targeting pathogen drug efflux, a key antimycobacterial drug resistance mechanism, is an attractive, viable strategy for the development of new TB therapeutics. Methods In this study, we utilised <ns3:italic>Mycobacterium smegmatis</ns3:italic> ( <ns3:italic>Msm</ns3:italic> ), a non-pathogenic <ns3:italic>Mtb</ns3:italic> surrogate, to delineate the ability of natural-product based compounds to augment the efficacy of bedaquiline (BDQ), clofazimine (CFZ) and doxycycline (DOX), probably via efflux inhibition (EI). Literature reporting the plant sources of the known efflux inhibitors (EIs) reserpine (RES), berberine (BER) and piperine (PIP) was scoped and additional compounds, (+)-lyoniresinol-3-Alpha-O-Beta-D-glucopyranoside (LYO-3) and lyoniresinol (LYO), isolated from the same plant species were chosen for testing. <ns3:italic>In vitro</ns3:italic> screening of the selected compounds was performed using the two-dimensional (2-D) checkerboard assay in which each likely efflux disruptor was tested in combination with BDQ, CFZ and DOX against <ns3:italic>Msm</ns3:italic> and the effect of the combinations ascertained. Thereafter, compounds that exhibited probable EI activity were docked onto potential targets namely MSMEG_5187, a <ns3:italic>Msm</ns3:italic> homologue of <ns3:italic>Mtb</ns3:italic> Rv1258c efflux pump (EP) and MmpL5. Results Molecular docking revealed that the EIs avidly bound to the EPs with docking scores of &lt;-7 kcal/mol while the checkerboard combination assays demonstrated strong synergistic interactions for BDQ plus BER, LYO-3 and LYO. Conclusion These results point to a probable disruption of the <ns3:italic>Msm</ns3:italic> efflux system by <ns3:italic>Berberis species</ns3:italic> derivatives. </ns3:p>

Authors

Publication Details

Journal
Open Research Africa
Published
2026-02-22
DOI
https://doi.org/10.12688/openresafrica.16071.2
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Potentiation of the antimycobacterial activity of bedaquiline, clofazimine, and doxycycline against Mycobacterium smegmatis by several natural product-based compounds is putatively via efflux inhibition

Ephantus G. Ndirangu, Eric M. Guantai, Edwin Mutuma Murungi, Caroline Maina et al.
Open Research Africa
Tuberculosis Research and Epidemiology
article

Potentiation of the antimycobacterial activity of bedaquiline, clofazimine, and doxycycline against Mycobacterium smegmatis by several natural product-based compounds is putatively via efflux inhibition

Ephantus G. Ndirangu, Eric M. Guantai, Edwin Mutuma Murungi, Caroline Maina, James Mugo, Robi Chacha, Mathew P. Ngugi, Elizabeth Kigondu, Sospeter Ngoci Njeru
article en

Abstract

<ns3:p> Background <ns3:italic>Mycobacterium tuberculosis</ns3:italic> ( <ns3:italic>Mtb</ns3:italic> ), the causative agent of tuberculosis (TB), is the leading cause of death due to a single infectious pathogen globally. The increasing prevalence of drug-resistant <ns3:italic>Mtb</ns3:italic> strains underscores the pressing need for the development of new antimycobacterial drugs with novel mechanisms of action. Targeting pathogen drug efflux, a key antimycobacterial drug resistance mechanism, is an attractive, viable strategy for the development of new TB therapeutics. Methods In this study, we utilised <ns3:italic>Mycobacterium smegmatis</ns3:italic> ( <ns3:italic>Msm</ns3:italic> ), a non-pathogenic <ns3:italic>Mtb</ns3:italic> surrogate, to delineate the ability of natural-product based compounds to augment the efficacy of bedaquiline (BDQ), clofazimine (CFZ) and doxycycline (DOX), probably via efflux inhibition (EI). Literature reporting the plant sources of the known efflux inhibitors (EIs) reserpine (RES), berberine (BER) and piperine (PIP) was scoped and additional compounds, (+)-lyoniresinol-3-Alpha-O-Beta-D-glucopyranoside (LYO-3) and lyoniresinol (LYO), isolated from the same plant species were chosen for testing. <ns3:italic>In vitro</ns3:italic> screening of the selected compounds was performed using the two-dimensional (2-D) checkerboard assay in which each likely efflux disruptor was tested in combination with BDQ, CFZ and DOX against <ns3:italic>Msm</ns3:italic> and the effect of the combinations ascertained. Thereafter, compounds that exhibited probable EI activity were docked onto potential targets namely MSMEG_5187, a <ns3:italic>Msm</ns3:italic> homologue of <ns3:italic>Mtb</ns3:italic> Rv1258c efflux pump (EP) and MmpL5. Results Molecular docking revealed that the EIs avidly bound to the EPs with docking scores of &lt;-7 kcal/mol while the checkerboard combination assays demonstrated strong synergistic interactions for BDQ plus BER, LYO-3 and LYO. Conclusion These results point to a probable disruption of the <ns3:italic>Msm</ns3:italic> efflux system by <ns3:italic>Berberis species</ns3:italic> derivatives. </ns3:p>

Open Research AfricaVol. 8
Good health and well-being
Openalex Percentile: Top 46%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.